NICE require a broad range of evidence to be included within the reimbursement dossier, including cl...
Read moreAccording to data from the Ministry of Health 65.1% of medicines admitted to reimbursement in 2021 w...
Read moreThis reforms have been welcomed by the industry as they should support faster access to medicines as...
Read moreAll other aspects of the voluntary scheme remain unchanged.
Read moreThe changes cover how topics are chosen, the steps and stages in each evaluation and how evidence is...
Read moreThe report looks at four possible scenarios including most notably the creation of a “grande Sécu...
Read moreThe Court has annulled the inclusion of the orphan drug Onivyde (irinotecan) in the reference price ...
Read moreThe association proposes concentrating efforts around four primary objectives.
Read moreIn addition to new cancer drugs, the G-BA also evaluated the first antiviral drug to treat COVID-19 ...
Read moreNotably, the early access scheme was reformed with effect from 1st July 2021.
Read more